dp – -Translation – Keybot Dictionary

Spacer TTN Translation Network TTN TTN Login Deutsch Français Spacer Help
Source Languages Target Languages
Keybot 10 Results  www.pmprb-cepmb.gc.ca
  Spriafil  
Show textShow cached sourceOpen source URL
24. Ullmann AJ, Cornely OA, Burchardt A, Hachem R, Kontoyiannis DP, Topelt K et al. Pharmacokinetics, safety and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection.
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine pmprb-cepmb.gc.ca as primary domain
20. Skiest DJ, Vazquez JA, Anstead GM, Graybill JR, Reynes J, Ward D et al. Poraconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection. Clin Infect Dis 2007;44:607-14.
  Spriafil  
Show textShow cached sourceOpen source URL
23. van Burik JAH, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP. Posaconazole is effective as salvage thaerpy in zygomycosis : a retrospective summary of 91 cases. Clin Infect Dis 2006;42:e61-65.
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine pmprb-cepmb.gc.ca as primary domain
19. Walsh TJ, Raad I, Patterson TF, Chandrasekar P, Donowitz GR, Graybill, Greene RE et al. Treatment of invasiv aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy : an externally controlled trial. CID 2007 January 1;442:2-12.
  Spriafil  
Show textShow cached sourceOpen source URL
21. Raad II, Hachem RY, Herbrecht R, Graybill JR, Hare R, Corcoran G, Kontoyiannis DP. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions.
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine pmprb-cepmb.gc.ca as primary domain
17. Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007 Jan 25;356(4):335-47.
  Ketek  
Show textShow cached sourceOpen source URL
Noorby SR, Chang J, Stewart JA, Brumpt I, Conway DP. Relief of symptoms in patients with Group A beta hemolytic streptococcus tonsilopharyngitis: comparison between telithromycin and penicillin V. Scand J Infect Dis 2003; 35:223-5.
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine pmprb-cepmb.gc.ca as primary domain
Noorby SR, Chang J, Stewart JA, Brumpt I, Conway DP. Relief of symptoms in patients with Group A beta hemolytic streptococcus tonsilopharyngitis: comparison between telithromycin and penicillin V. Scand J Infect Dis 2003;35:223-5.
  Tarceva  
Show textShow cached sourceOpen source URL
17. Herbst RS, Johnson DH, Mininberg E, Carbone DP, Henderson T, Kim ES, et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer.
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine pmprb-cepmb.gc.ca as primary domain
17. Herbst RS, Johnson DH, Mininberg E, Carbone DP, Henderson T, Kim ES, et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol. 2005 Apr 10; 23(11):2544-55.